- Trial phase
- Phase 1 completed; Phase 2 planned
- Time to market
- If Phase 2 trials begin in late 2026 or early 2027, topline data would likely be 12-18 months out. Assuming positive Phase 2 and Phase 3 results, potential FDA approval would be several years away, likely 2029 or later.
- Why 4/10
- SEP-631 completed Phase 1 with positive data in March 2026 (past catalyst). The next hard catalyst would be Phase 2 topline data in chronic spontaneous urticaria, but no specific readout date has been announced; Phase 2 initiation is likely in progress but data remains 12+ months out. SEP-631 is a major pipeline asset but not the company's only program (SEP-479 and SEP-204 are also advancing). Impact score of 4 reflects a mid-stage drug with no imminent binary catalyst.
Watch for Septerna's Q3 2026 earnings call and press release (filed Nov 9, 2026) for updates on SEP-631 Phase 2 trial initiation timeline in chronic spontaneous urticaria. The next major catalyst is Phase 2 topline data, likely 12-18 months out. SEP-479 (PTH1R agonist for hypoparathyroidism) Phase 1 data is another pipeline catalyst to monitor.
Price Chart
Executive Summary
SEP-631 is an oral small-molecule drug from Septerna, Inc. (NASDAQ: SEPN) that targets MRGPRX2, a receptor on mast cells involved in allergic-type reactions. It completed a Phase 1 trial in healthy volunteers with positive results announced in March 2026, showing robust, dose-dependent suppression of mast cell activity and a safety profile comparable to placebo. Septerna plans to advance SEP-631 into Phase 2 development for chronic spontaneous urticaria (CSU) and chronic inducible urticaria. The CSU market is competitive with several approved therapies (Xolair, Dupixent, remibrutinib) and other candidates in development. SEPN trades near its 52-week high of ~$51 with a Strong Buy analyst consensus and a mean price target of $56.78, reflecting 14% upside. The stock has rallied over 315% from mid-2025 levels, pricing in significant pipeline optimism ahead of Phase 2 data.
How It Works
SEP-631 is an oral pill that blocks a specific receptor called MRGPRX2 found on mast cells (a type of immune cell). When this receptor is overactive, it triggers mast cells to release histamine and other inflammatory chemicals, causing hives, itching, and swelling. By dialing down this receptor's activity, SEP-631 aims to prevent those allergic-type reactions at their source, offering a potential treatment for chronic hives and other mast cell-driven conditions.
Trial Status
Phase 1 trial in healthy volunteers completed with positive data announced March 1, 2026 and presented at the AAAAI annual meeting. The trial evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics. SEP-631 demonstrated robust, dose-dependent inhibition of icatibant-induced skin wheal formation with complete inhibition at doses as low as 10 mg once-daily. It was well-tolerated across all doses with an adverse event profile comparable to placebo. Septerna plans to advance SEP-631 into Phase 2 development in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), and is evaluating potential in additional mast cell-driven indications including atopic dermatitis, interstitial cystitis, migraine, and asthma.
The Two-Sided Case
Upcoming Catalysts
- Phase 2 trial initiation in CSU and/or CIndU (timing to be announced; anticipated in the Q3 2026 earnings update filed Nov 9, 2026)
- Phase 2 topline data (likely 12-18 months after initiation)
- Potential expansion into additional mast cell-driven indications (atopic dermatitis, interstitial cystitis, migraine, asthma)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Septerna, Inc. PRESS-RELEASE SEPN ·Originating report